应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MTVA MetaVia Inc
盘前交易 03-10 07:30:00 EDT
1.44
-0.11
-7.10%
盘前
1.44
+0.00
0.00%
06:58 EDT
最高
1.65
最低
1.34
成交量
24.60万
今开
1.56
昨收
1.55
日振幅
20.00%
总市值
461.98万
流通市值
329.53万
总股本
320.82万
成交额
37.00万
换手率
10.75%
流通股本
228.84万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Metavia Inc.盘中异动 下午盘急速上涨5.30%
市场透视 · 03-03
Metavia Inc.盘中异动 下午盘急速上涨5.30%
Metavia Inc.盘中异动 股价大涨5.30%报1.59美元
市场透视 · 02-24
Metavia Inc.盘中异动 股价大涨5.30%报1.59美元
MetaVia Inc与Syntekabio合作AI建模获突破进展 确认Vanoglipel关键治疗靶点
美股速递 · 02-04
MetaVia Inc与Syntekabio合作AI建模获突破进展 确认Vanoglipel关键治疗靶点
MetaVia公布Da-1726代谢疾病一期B临床试验积极结果——显著血糖控制、直接肝脏效应突出、减重效果强劲且安全性良好
美股速递 · 01-05
MetaVia公布Da-1726代谢疾病一期B临床试验积极结果——显著血糖控制、直接肝脏效应突出、减重效果强劲且安全性良好
Metavia Inc.盘中异动 早盘急速下挫5.21%
市场透视 · 2025-11-12
Metavia Inc.盘中异动 早盘急速下挫5.21%
暂无数据
公司概况
公司名称:
MetaVia Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
MetaVia Inc.于2008年11月10日在密歇根以Michigan Life Therapeutics, LLC (MLT)这个名字注册成立。NeuroBo Pharmaceuticals, Inc.是一家临床阶段的生物技术公司,主要致力于开发和商业化治疗心脏代谢疾病的新药物。NeuroBo有两个主要项目,重点治疗非酒精性脂肪性肝炎(NASH)、肥胖症和2型糖尿病(T2D)。
发行价格:
--
{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.44,"timestamp":1773086400000,"preClose":1.55,"halted":0,"volume":245959,"hourTrading":{"tag":"盘前","latestPrice":1.44,"preClose":1.44,"latestTime":"06:58 EDT","volume":2008,"amount":2983.619932,"timestamp":1773140304860,"change":0,"changeRate":0,"amplitude":0.055556},"delay":0,"changeRate":-0.07096774193548393,"floatShares":2288400,"shares":3208200,"eps":-11.363935,"marketStatus":"盘前交易","change":-0.11,"latestTime":"03-10 07:30:00 EDT","open":1.56,"high":1.65,"low":1.34,"amount":370011.1763908,"amplitude":0.2,"askPrice":1.62,"askSize":122,"bidPrice":1.43,"bidSize":411,"shortable":0,"etf":0,"ttmEps":-11.363935,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773149400000},"marketStatusCode":1,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.44,"preHourTrading":{"tag":"盘前","latestPrice":1.44,"preClose":1.44,"latestTime":"06:58 EDT","volume":2008,"amount":2983.619932,"timestamp":1773140304860,"change":0,"changeRate":0,"amplitude":0.055556},"postHourTrading":{"tag":"盘后","latestPrice":1.5,"preClose":1.44,"latestTime":"19:40 EDT","volume":15372,"amount":22595.2364,"timestamp":1773099603444,"change":0.06,"changeRate":0.041667,"amplitude":0.083333},"volumeRatio":2.18309259117556},"requestUrl":"/m/hq/s/MTVA/tweets","defaultTab":"tweets","newsList":[{"id":"2616036393","title":"Metavia Inc.盘中异动 下午盘急速上涨5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616036393","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616036393?lang=zh_cn&edition=full","pubTime":"2026-03-03 03:37","pubTimestamp":1772480262,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日03时37分,Metavia Inc.股票出现波动,股价快速上涨5.30%。截至发稿,该股报1.59美元/股,成交量4.7403万股,换手率1.43%,振幅5.30%。Metavia Inc.股票所在的生物技术行业中,整体跌幅为0.34%。Metavia Inc.公司简介:MetaVia Inc是一家临床阶段的生物技术公司,专注于开发治疗心脏代谢疾病的新型药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030303374297a7b44c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030303374297a7b44c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MTVA","BK4202","BK4139","OXM"],"gpt_icon":0},{"id":"2614461177","title":"Metavia Inc.盘中异动 股价大涨5.30%报1.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614461177","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614461177?lang=zh_cn&edition=full","pubTime":"2026-02-24 23:04","pubTimestamp":1771945446,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日23时04分,Metavia Inc.股票出现异动,股价快速拉升5.30%。截至发稿,该股报1.59美元/股,成交量7123股,换手率0.21%,振幅2.07%。Metavia Inc.股票所在的生物技术行业中,整体涨幅为0.34%。Metavia Inc.公司简介:MetaVia Inc是一家临床阶段的生物技术公司,专注于开发治疗心脏代谢疾病的新型药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022423040697a6e1bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022423040697a6e1bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MTVA","OXM","BK4202"],"gpt_icon":0},{"id":"1150245570","title":"MetaVia Inc与Syntekabio合作AI建模获突破进展 确认Vanoglipel关键治疗靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1150245570","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150245570?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:06","pubTimestamp":1770210383,"startTime":"0","endTime":"0","summary":"MetaVia Inc公布其与Syntekabio持续合作中人工智能建模研究的积极成果。最新数据证实,双方共同开发的糖尿病肾病治疗药物Vanoglipel已通过AI模型精准锁定关键治疗靶点。\n这项突破性进展标志着AI驱动药物研发模式在复杂疾病领域的应用迈出重要一步。通过深度学习算法分析海量生物医学数据,研究团队成功验证了Vanoglipel作用于肾脏纤维化与炎症通路的核心机制。\n合作双方表示,该成果将显著加速Vanoglipel的临床前开发进程。AI建模不仅缩短了传统靶点确认周期,更通过多维度模拟预测了化合物与靶点相互作用的特异性,为后续药物优化提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"1148649541","title":"MetaVia公布Da-1726代谢疾病一期B临床试验积极结果——显著血糖控制、直接肝脏效应突出、减重效果强劲且安全性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1148649541","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148649541?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:30","pubTimestamp":1767619821,"startTime":"0","endTime":"0","summary":"MetaVia Inc宣布其针对代谢疾病的候选药物Da-1726在一期B期临床试验中取得具有统计学意义的积极数据。该试验结果显示,Da-1726不仅能有效调控血糖水平,还展现出对肝脏的直接作用机制。此外,受试者在接受治疗后出现显著的体重下降,同时药物整体安全性表现优异,未出现严重不良反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2583531690","title":"Metavia Inc.盘中异动 早盘急速下挫5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583531690","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583531690?lang=zh_cn&edition=full","pubTime":"2025-11-12 23:41","pubTimestamp":1762962109,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日23时41分,Metavia Inc.股票出现异动,股价快速下跌5.21%。Metavia Inc.股票所在的生物技术行业中,整体涨幅为0.88%。其相关个股中,Leap Therapeutics, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大,Salarius Pharmaceuticals, Inc.、Leap Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃,换手率分别为6158.01%、521.51%、381.17%,振幅较大的相关个股有Leap Therapeutics, Inc.、Salarius Pharmaceuticals, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 ,振幅分别为115.43%、47.96%、47.55%。Metavia Inc.公司简介:MetaVia Inc是一家临床阶段的生物技术公司,专注于开发治疗心脏代谢疾病的新型药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112234149a49cc80f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251112234149a49cc80f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4202","MTVA","OXM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurobopharma.com","stockEarnings":[{"period":"1week","weight":-0.0588},{"period":"1month","weight":-0.2088},{"period":"3month","weight":-0.8333},{"period":"6month","weight":-0.8071},{"period":"1year","weight":-0.9155},{"period":"ytd","weight":-0.829}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"MetaVia Inc.于2008年11月10日在密歇根以Michigan Life Therapeutics, LLC (MLT)这个名字注册成立。NeuroBo Pharmaceuticals, Inc.是一家临床阶段的生物技术公司,主要致力于开发和商业化治疗心脏代谢疾病的新药物。NeuroBo有两个主要项目,重点治疗非酒精性脂肪性肝炎(NASH)、肥胖症和2型糖尿病(T2D)。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.000503},{"month":2,"riseRate":0.3,"avgChangeRate":0.007282},{"month":3,"riseRate":0.5,"avgChangeRate":-0.015227},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.143887},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.109293},{"month":6,"riseRate":0.555556,"avgChangeRate":0.090563},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.026489},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.189997},{"month":9,"riseRate":0.4,"avgChangeRate":0.065402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.186131},{"month":11,"riseRate":0.3,"avgChangeRate":-0.112358},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供MetaVia Inc(MTVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}